Fast, convenient access to information and services to help you treat the Exocrine Pancreatic Insufficiency (EPI) patients you see in your practice. VIVUS is committed to helping ensure access to PANCREAZE. Patients may pay as little as $0.*
Your all-access account will connect you to a range of services. Please note that this website is intended for US Healthcare Professionals. Before beginning the registration process, make sure to gather your practice address and license information — you’ll need them when creating your account.
* Eligible patients may pay as little as $0 on their co-pay for their PANCREAZE prescription with a maximum benefit of up to $100 per prescription fill (30-day supply) per month.
PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).
Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.
To avoid irritation of oral mucosa, do not chew PANCREAZE or retain in the mouth.
There is theoretical risk of viral transmission with all pancreatic enzyme products including PANCREAZE.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
Most common adverse reactions are: abdominal pain, flatulence, diarrhea, abnormal feces, and fatigue.
PANCREAZE is not interchangeable with any other pancrelipase products.
Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.
References: 1. PANCREAZE Full Prescribing Information. Campbell, CA: VIVUS, Inc; 2018.
2. Trapnell BC, et al. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2011;10(5):350-35 6.
Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).VIEW ALL +